Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Multi-kinase-IN-4 (compound 5d) is a multi-targeted kinase inhibitor active against VEGFR2, EGFR, HER2, and CDK2, with respective IC50 values of 0.33, 0.22, 0.18, and 2.09 μM. It exhibits broad-spectrum anti-cancer properties in HepG2, MCF-7, MDA-231, and HeLa cell lines, with IC50 values ranging from 1.94 to 7.1 µM, and demonstrates lower toxicity in WI-38 cells (IC50 = 40.85 µM). Additionally, it induces apoptosis and causes S-phase cell cycle arrest in HepG2 cells, and holds potential for cancer research [1].
説明 | Multi-kinase-IN-4 (compound 5d) is a multi-targeted kinase inhibitor active against VEGFR2, EGFR, HER2, and CDK2, with respective IC50 values of 0.33, 0.22, 0.18, and 2.09 μM. It exhibits broad-spectrum anti-cancer properties in HepG2, MCF-7, MDA-231, and HeLa cell lines, with IC50 values ranging from 1.94 to 7.1 µM, and demonstrates lower toxicity in WI-38 cells (IC50 = 40.85 µM). Additionally, it induces apoptosis and causes S-phase cell cycle arrest in HepG2 cells, and holds potential for cancer research [1]. |
ターゲット&IC50 | CDK2:2.09 μM, VEGFR2:0.33 μM, HER2:0.18 mM |
In vitro | Multi-kinase-IN-4 (compound 5d) demonstrates cytotoxicity against HepG2, MCF-7, MDA-231, and HeLa cell lines with IC50 values of 7.10, 2.48, 1.94, and 6.38 µM, respectively, after 48 hours of exposure, but exhibits lower cytotoxic activity towards WI38 cells (IC50 = 64.29 µM) [1]. When administered to HepG2 cells at a concentration of 7.1 µM for 24 hours, compound 5d increases the percentage of cells in S phase by 9.23% while decreasing the populations in G0-G1 and G2/M phases by 4.50% and 4.73%, respectively [1]. Additionally, Multi-kinase-IN-4 at 7.1 µM, over 24 hours, induces early and late apoptosis in HepG2 cells as well as necrotic cell death, with respective proportions of 7.51%, 3.45%, and 3.08% [1]. |
分子量 | 402.91 |
分子式 | C21H20ClFN2OS |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Multi-kinase-IN-4 Angiogenesis Tyrosine Kinase/Adaptors VEGFR Inhibitor inhibitor inhibit